Skip to main content

Table 1 Baseline characteristics

From: The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Characteristic Total patients (N = 2,200)
Mean age, mean (SD), years 69.3 (9.9)
Age category, n (%), years
 40–59 414 (18.8)
 60–64 268 (12.2)
 65–74 824 (37.5)
 75–84 576 (26.2)
  ≥ 85 118 (5.4)
Female, n (%) 1,098 (49.9)
Insurance type, n (%)
 Commercial 666 (30.3)
 Medicare Advantage 1,534 (69.7)
Charlson comorbidity score, mean (SD) 1.5 (1.5)
Baseline (6 month) COPD exacerbations, mean (SD) 0.7 (0.9)
 Severe 0.1 (0.4)
 Moderate 0.6 (0.8)
Comorbidities, n (%)
 COPD and bronchiectasis 2,154 (97.9)
 Hypertension 1,417 (64.4)
 Other lower respiratory disease 1,353 (61.5)
 Disorders of lipid metabolism 1,215 (55.2)
 Asthma 380 (17.3)
Baseline maintenance therapy use, n (%)
 LAMA 624 (28.4)
 ICS 138 (6.3)
 ICS/LABA 584 (26.6)
Baseline respiratory medication use, n (%)
 OCS 836 (38.0)
 SABA 899 (40.9)
 SAMA 65 (3.0)
 SAMA/SABA 252 (11.5)
  1. COPD chronic obstructive pulmonary disease, CPI consumer price index, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, OCS oral corticosteroid, SABA short-acting β2-agonist, SAMA short-acting muscarinic antagonist, SD standard deviation